ArticleBrain & spine2026
Incidence, risk factors, clinical and cognitive impact of secondary hemorrhage after spontaneous aneurysmal subarachnoid hemorrhage.
Article in Brain & spine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evidence on secondary hemorrhage (SH) in patients with spontaneous aneurysmal subarachnoid hemorrhage (aSAH) is limited. Most studies focus external ventricular drain (EVD)-related bleeding, while data on hemorrhage types, particularly under peri-interventional antiplatelet therapy (PIAT), are scarce. Research question: To investigate the incidence, risk factors, and clinical impact of SH after aSAH, including the role of PIAT. Material and methods: In this registry-based two-centre study we retrospectively analyzed 170 patients with aSAH treated between September 2021 and June 2025. EVD placement was performed in 128 patients; 120 underwent endovascular treatment, and 78 received PIAT. SH was classified as intracranial or peripheral. Functional and cognitive outcome were assessed using the modified Rankin Scale and the Montreal Cognitive Assessment, respectively, at admission, discharge, and three months. Results: SH occurred in 39% of patients. Intracranial hemorrhages predominated, with drain-associated (29%), aneurysm rebleeding (27%), and access-related hemorrhages (21%) being most frequent. EVD placement was independently associated with SH (OR 5.07, p = 0.002). No significant association between PIAT and SH was observed. SH was associated with worse functional and cognitive outcomes, however, age and WFNS grade were the main independent predictors. Discussion and conclusion: SH after aSAH is common and reflects a heterogeneous spectrum of bleeding events. The association with EVD likely reflects disease severity rather than causality. No association between PIAT and SH was found, although analyses were limited. SH appears to be a marker of disease severity associated with worse early outcomes, emphasizing careful procedural management and individualized risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.